URGN — Urogen Pharma Cashflow Statement
0.000.00%
Last trade - 00:00- $482.83m
- $444.41m
- $82.71m
- 47
- 18
- 61
- 38
Annual cashflow statement for Urogen Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -105 | -128 | -111 | -110 | -102 |
| Depreciation | |||||
| Non-Cash Items | 30.4 | 30.1 | 39.4 | 27.6 | 21.7 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 3.41 | -7.91 | -14.3 | -6.31 | 3.34 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -71 | -106 | -84.9 | -87.6 | -76.4 |
| Capital Expenditures | -0.325 | -1.22 | -0.752 | -0.254 | -0.194 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -145 | 94.5 | 4.82 | 1.31 | -0.759 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -146 | 93.2 | 4.07 | 1.06 | -0.953 |
| Financing Cash Flow Items | -0.076 | -0.066 | 72.3 | -0.16 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 165 | 16.5 | 72.3 | 97.1 | 117 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -51.4 | 3.88 | -8.5 | 10.6 | 39.6 |